Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Johann, Foloppe"'
Autor:
Laetitia Fend, Eric Quemeneur, Jean-Baptiste Marchand, Nathalie Silvestre, Johann Foloppe, Christelle Remy, Patricia Kleinpeter, Jules Deforges, Fadi Azar, Christelle Demeusoit, Clémentine Spring-Giusti
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background TG6050 was designed as an improved oncolytic vector, combining the intrinsic properties of vaccinia virus to selectively replicate in tumors with the tumor-restricted expression of recombinant immune effectors to modify the tumor immune ph
Externí odkaz:
https://doaj.org/article/51ec8ad7965d4c9fa9fa907be1c0686c
Autor:
Jérémy Béguin, Eve Laloy, Sandrine Cochin, Murielle Gantzer, Isabelle Farine, Christelle Pichon, Baptiste Moreau, Johann Foloppe, Jean-Marc Balloul, Christelle Machon, Jérôme Guitton, Dominique Tierny, Bernard Klonjkowski, Eric Quéméneur, Christelle Maurey, Philippe Erbs
Publikováno v:
Molecular Therapy: Oncolytics, Vol 30, Iss , Pp 103-116 (2023)
TG6002 is an oncolytic vaccinia virus expressing FCU1 protein, which converts 5-fluorocytosine into 5-fluorouracil. The study objectives were to assess tolerance, viral replication, 5-fluorouracil synthesis, and tumor microenvironment modifications t
Externí odkaz:
https://doaj.org/article/158089590f2b4c318c0aec5c6f69e200
Autor:
Jérémy Béguin, Murielle Gantzer, Isabelle Farine, Johann Foloppe, Bernard Klonjkowski, Christelle Maurey, Éric Quéméneur, Philippe Erbs
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract Oncolytic virotherapy is an emerging strategy that uses replication-competent viruses to kill tumor cells. We have reported the oncolytic effects of TG6002, a recombinant oncolytic vaccinia virus, in preclinical human xenograft models and ca
Externí odkaz:
https://doaj.org/article/68a68d93323c4c66a8300f3d5dd7b61e
Autor:
Jérémy Béguin, Johann Foloppe, Christelle Maurey, Eve Laloy, Julie Hortelano, Virginie Nourtier, Christelle Pichon, Sandrine Cochin, Pascale Cordier, Hélène Huet, Eric Quemeneur, Bernard Klonjkowski, Philippe Erbs
Publikováno v:
Molecular Therapy: Oncolytics, Vol 19, Iss , Pp 57-66 (2020)
Oncolytic virotherapy is a promising therapeutic approach for the treatment of cancer. TG6002 is a recombinant oncolytic vaccinia virus deleted in the thymidine kinase and ribonucleotide reductase genes and armed with the suicide gene FCU1, which enc
Externí odkaz:
https://doaj.org/article/1fe5445d87ae40e3b035d2874094f1d4
Autor:
Tiphaine Delaunay, Joelle Nader, Marion Grard, Isabelle Farine, Vera Hedwig, Johann Foloppe, Thibaut Blondy, Mathilde Violland, Daniel Pouliquen, Marc Grégoire, Nicolas Boisgerault, Philippe Erbs, Jean-François Fonteneau
Publikováno v:
Molecular Therapy: Oncolytics, Vol 18, Iss , Pp 573-578 (2020)
Malignant pleural mesothelioma (MPM) is a cancer of the pleura that lacks efficient treatment. Oncolytic immunotherapy using oncolytic vaccinia virus (VV) may represent an alternative therapeutic approach for the treatment of this malignancy. Here, w
Externí odkaz:
https://doaj.org/article/6d67b79df4734bc992cb612a228e36e2
Autor:
Jérémy Béguin, Virginie Nourtier, Murielle Gantzer, Sandrine Cochin, Johann Foloppe, Jean-Marc Balloul, Eve Laloy, Dominique Tierny, Bernard Klonjkowski, Eric Quemeneur, Christelle Maurey, Philippe Erbs
Publikováno v:
BMC Veterinary Research, Vol 16, Iss 1, Pp 1-13 (2020)
Abstract Background Cancer is a leading cause of mortality for both humans and dogs. As spontaneous canine cancers appear to be relevant models of human cancers, developing new therapeutic approaches could benefit both species. Oncolytic virotherapy
Externí odkaz:
https://doaj.org/article/666a4864aeef47ff810d542fe80715cf
Autor:
Laetitia Fend, Eric Quemeneur, Monika Semmrich, Jean-Baptiste Marchand, Matilda Rehn, Nathalie Silvestre, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Björn Frendeus, Petra Holmkvist, Carolin Svensson, Christelle Remy, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L Cleary, Mimoza Bodén
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/715bfd92355a4c01a650b6be33e6abb9
Autor:
Johann Foloppe, Juliette Kempf, Nicolas Futin, Jacqueline Kintz, Pascale Cordier, Christelle Pichon, Annie Findeli, Fabien Vorburger, Eric Quemeneur, Philippe Erbs
Publikováno v:
Molecular Therapy: Oncolytics, Vol 14, Iss , Pp 1-14 (2019)
Oncolytic vaccinia viruses are currently in clinical development. However, the safety and the tumor selectivity of these oncolytic viruses must be improved. We previously constructed a first-generation oncolytic vaccinia virus by expressing the suici
Externí odkaz:
https://doaj.org/article/35a655137d434081af3a44ab9dfcb826
Autor:
Adrian Pelin, Johann Foloppe, Julia Petryk, Ragunath Singaravelu, Marian Hussein, Florian Gossart, Victoria A. Jennings, Lawton J. Stubbert, Madison Foster, Christopher Storbeck, Antonio Postigo, Elena Scut, Brian Laight, Michael Way, Philippe Erbs, Fabrice Le Boeuf, John C. Bell
Publikováno v:
Molecular Therapy: Oncolytics, Vol 14, Iss , Pp 246-252 (2019)
Vaccinia virus (VACV) possesses a great safety record as a smallpox vaccine and has been intensively used as an oncolytic virus against various types of cancer over the past decade. Different strategies were developed to make VACV safe and selective
Externí odkaz:
https://doaj.org/article/5d24d17ce15143d1abecc60ad4722916
Autor:
Laetitia Fend, Eric Quemeneur, Monika Semmrich, Jean-Baptiste Marchand, Matilda Rehn, Nathalie Silvestre, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Björn Frendeus
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/60f9adc19c7a452191469affca81e1df